Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles Published September 2019 Citation Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC. . World Conference on Lung Cancer. . Authors:Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC Sources:World Conference on Lung Cancer Share Posted inPublicationsUnmet need More publicationsESMOOctober 2025Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practiceBrufsky A, Layman R, Liu X, et al.Publication summaryPublicationsComparative effectivenessBreast cancerESMOOctober 2025Real-world treatment patterns and outcomes in US patients with neurotrophic tyrosine receptor kinase–positive solid tumorsSu, I, Flores Avile C, Huang P, et al. Publication summaryPublicationsTreatment patternsESMO OpenSeptember 2025Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practiceRugo H, Layman R, Lynce F, et al.Publication summaryPublicationsComparative effectivenessMetastatic breast cancerBreast cancer